Welcome to
On Feet Nation
Thomas Shaw Online
Satish Mehta, MD & CEO, Emcure Pharma is currently having a moment under the sun. Emcure’s subsidiary, Gennova, is developing India’s first indigenously developed mRNA COVID-19 vaccine that is currently undergoing phase II and phase III trials. Mehta is confident about meeting the said target of 60 million doses by the end of 2021, despite the logistics challenges. The company is working towards backward integration of its operations to help de-risk the supply chain.
Read more athttps://www.entrepreneur.com/article/395858
© 2024 Created by PH the vintage. Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation